Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Journal of Neuroinflammation
Published in: Journal of Neuroinflammation 1/2012

Open Access 01-12-2012 | Research

TGFβ signalling plays an important role in IL4-induced alternative activation of microglia

Authors: Xiaolai Zhou, Björn Spittau, Kerstin Krieglstein

Published in: Journal of Neuroinflammation | Issue 1/2012

Login to get access

Abstract

Background

Microglia are the resident immune cells of the central nervous system and are accepted to be involved in a variety of neurodegenerative diseases. Several studies have demonstrated that microglia, like peripheral macrophages, exhibit two entirely different functional activation states, referred to as classical (M1) and alternative (M2) activation. TGFβ is one of the most important anti-inflammatory cytokines and its effect on inhibiting microglia or macrophage classical activation has been extensively studied. However, the role of TGFβ during alternative activation of microglia has not been described yet.

Methods

To investigate the role of TGFβ in IL4-induced microglia alternative activation, both, BV2 as well as primary microglia from new born C57BL/6 mice were used. Quantitative RT-PCR and western blots were performed to detect mRNA and protein levels of the alternative activation markers Arginase1 (Arg1) and Chitinase 3-like 3 (Ym1) after treatment with IL4, TGFβ or both. Endogenous TGFβ release after IL4 treatment was evaluated using the mink lung epithelial cell (MLEC) assay and a direct TGFβ2 ELISA. TGFβ receptor type I inhibitor and MAPK inhibitor were applied to address the involvement of TGFβ signalling and MAPK signalling in IL4-induced alternative activation of microglia.

Results

TGFβ enhances IL4-induced microglia alternative activation by strongly increasing the expression of Arg1 and Ym1. This synergistic effect on Arg1 induction is almost completely blocked by the application of the MAPK inhibitor, PD98059. Further, treatment of primary microglia with IL4 increased the expression and secretion of TGFβ2, suggesting an involvement of endogenous TGFβ in IL4-mediated microglia activation process. Moreover, IL4-mediated induction of Arg1 and Ym1 is impaired after blocking the TGFβ receptor I indicating that IL4-induced microglia alternative activation is dependent on active TGFβ signalling. Interestingly, treatment of primary microglia with TGFβ alone results in up regulation of the IL4 receptor alpha, indicating that TGFβ increases the sensitivity of microglia for IL4 signals.

Conclusions

Taken together, our data reveal a new role for TGFβ during IL4-induced alternative activation of microglia and consolidate the essential functions of TGFβ as an anti-inflammatory molecule and immunoregulatory factor for microglia.
Literature
1.
Vaughan DW, Peters A: Neuroglial cells in the cerebral cortex of rats from young adulthood to old age: an electron microscope study. J Neurocytol 1974, 3:405–429.CrossRefPubMed
2.
Colton CA, Mott RT, Sharpe H, Xu Q, Van Nostrand WE, Vitek MP: Expression profiles for macrophage alternative activation genes in AD and in mouse models of AD. J Neuroinflammation 2006, 3:27.CrossRefPubMedPubMedCentral
3.
Colton CA, Wilcock DM: Assessing activation states in microglia. CNS Neurol Disord Drug Targets 2010, 9:174–191.CrossRefPubMed
4.
Shimizu E, Kawahara K, Kajizono M, Sawada M, Nakayama H: IL-4-induced selective clearance of oligomeric beta-amyloid peptide(1–42) by rat primary type 2 microglia. J Immunol 2008, 181:6503–6513.CrossRefPubMed
5.
Ponomarev ED, Maresz K, Tan Y, Dittel BN: CNS-derived interleukin-4 is essential for the regulation of autoimmune inflammation and induces a state of alternative activation in microglial cells. J Neurosci 2007, 27:10714–10721.CrossRefPubMed
6.
Ponomarev ED, Veremeyko T, Barteneva N, Krichevsky AM, Weiner HL: MicroRNA-124 promotes microglia quiescence and suppresses EAE by deactivating macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med 2011, 17:64–70.CrossRefPubMed
7.
Rojo AI, Innamorato NG, Martin-Moreno AM, De Ceballos ML, Yamamoto M, Cuadrado A: Nrf2 regulates microglial dynamics and neuroinflammation in experimental Parkinson’s disease. Glia 2010, 58:588–598.CrossRefPubMed
8.
Smith PF: Inflammation in Parkinson’s disease: an update. Curr Opin Investig Drugs 2008, 9:478–484.PubMed
9.
Rubartelli A, Lotze MT: Inside, outside, upside down: damage-associated molecular-pattern molecules (DAMPs) and redox. Trends Immunol 2007, 28:429–436.CrossRefPubMed
10.
11.
12.
Gao HM, Hong JS: Why neurodegenerative diseases are progressive: uncontrolled inflammation drives disease progression. Trends Immunol 2008, 29:357–365.CrossRefPubMedPubMedCentral
13.
Giulian D: Ameboid microglia as effectors of inflammation in the central nervous system. J Neurosci Res 1987, 18:155–171. 132–153CrossRefPubMed
14.
Block ML, Zecca L, Hong JS: Microglia-mediated neurotoxicity: uncovering the molecular mechanisms. Nat Rev Neurosci 2007, 8:57–69.CrossRefPubMed
15.
16.
17.
18.
Martinez FO, Helming L, Gordon S: Alternative activation of macrophages: an immunologic functional perspective. Annu Rev Immunol 2009, 27:451–483.CrossRefPubMed
19.
Bogdan C, Vodovotz Y, Nathan C: Macrophage deactivation by interleukin 10. J Exp Med 1991, 174:1549–1555.CrossRefPubMed
20.
Williams L, Jarai G, Smith A, Finan P: IL-10 expression profiling in human monocytes. J Leukoc Biol 2002, 72:800–809.PubMed
21.
Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA: Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 2006, 24:99–146.CrossRefPubMed
22.
23.
Griffiths MR, Gasque P, Neal JW: The multiple roles of the innate immune system in the regulation of apoptosis and inflammation in the brain. J Neuropathol Exp Neurol 2009, 68:217–226.CrossRefPubMed
24.
25.
Fadok VA, Bratton DL, Konowal A, Freed PW, Westcott JY, Henson PM: Macrophages that have ingested apoptotic cells in vitro inhibit proinflammatory cytokine production through autocrine/paracrine mechanisms involving TGF-beta, PGE2, and PAF. J Clin Invest 1998, 101:890–898.CrossRefPubMedPubMedCentral
26.
Blobe GC, Schiemann WP, Lodish HF: Role of transforming growth factor beta in human disease. N Engl J Med 2000, 342:1350–1358.CrossRefPubMed
27.
Feng XH, Derynck R: Specificity and versatility in tgf-beta signaling through Smads. Annu Rev Cell Dev Biol 2005, 21:659–693.CrossRefPubMed
28.
29.
Engel ME, McDonnell MA, Law BK, Moses HL: Interdependent SMAD and JNK signaling in transforming growth factor-beta-mediated transcription. J Biol Chem 1999, 274:37413–37420.CrossRefPubMed
30.
Abe M, Harpel JG, Metz CN, Nunes I, Loskutoff DJ, Rifkin DB: An assay for transforming growth factor-beta using cells transfected with a plasminogen activator inhibitor-1 promoter-luciferase construct. Anal Biochem 1994, 216:276–284.CrossRefPubMed
31.
Oh CK, Geba GP, Molfino N: Investigational therapeutics targeting the IL-4/IL-13/STAT-6 pathway for the treatment of asthma. Eur Respir Rev 2010, 19:46–54.CrossRefPubMed
32.
Le Y, Iribarren P, Gong W, Cui Y, Zhang X, Wang JM: TGF-beta1 disrupts endotoxin signaling in microglial cells through Smad3 and MAPK pathways. J Immunol 2004, 173:962–968.CrossRefPubMed
33.
Loane DJ, Stoica BA, Pajoohesh-Ganji A, Byrnes KR, Faden AI: Activation of metabotropic glutamate receptor 5 modulates microglial reactivity and neurotoxicity by inhibiting NADPH oxidase. J Biol Chem 2009, 284:15629–15639.CrossRefPubMedPubMedCentral
34.
Kitamura Y, Takahashi H, Matsuoka Y, Tooyama I, Kimura H, Nomura Y, Taniguchi T: In vivo induction of inducible nitric oxide synthase by microinjection with interferon-gamma and lipopolysaccharide in rat hippocampus. Glia 1996, 18:233–243.CrossRefPubMed
35.
36.
Munder M, Eichmann K, Modolell M: Alternative metabolic states in murine macrophages reflected by the nitric oxide synthase/arginase balance: competitive regulation by CD4+ T cells correlates with Th1/Th2 phenotype. J Immunol 1998, 160:5347–5354.PubMed
37.
Pauleau AL, Rutschman R, Lang R, Pernis A, Watowich SS, Murray PJ: Enhancer-mediated control of macrophage-specific arginase I expression. J Immunol 2004, 172:7565–7573.CrossRefPubMed
38.
Morris SM: Enzymes of arginine metabolism. J Nutr 2004, 134:2743S-2747S. discussion 2765S-2767SPubMed
39.
Gotoh T, Sonoki T, Nagasaki A, Terada K, Takiguchi M, Mori M: Molecular cloning of cDNA for nonhepatic mitochondrial arginase (arginase II) and comparison of its induction with nitric oxide synthase in a murine macrophage-like cell line. FEBS Lett 1996, 395:119–122.CrossRefPubMed
40.
Kepka-Lenhart D, Ash DE, Morris SM: Determination of mammalian arginase activity. Methods Enzymol 2008, 440:221–230.CrossRefPubMed
41.
Loke P, Gallagher I, Nair MG, Zang X, Brombacher F, Mohrs M, Allison JP, Allen JE: Alternative activation is an innate response to injury that requires CD4+ T cells to be sustained during chronic infection. J Immunol 2007, 179:3926–3936.CrossRefPubMed
42.
Hesse M, Modolell M, La Flamme AC, Schito M, Fuentes JM, Cheever AW, Pearce EJ, Wynn TA: Differential regulation of nitric oxide synthase-2 and arginase-1 by type 1/type 2 cytokines in vivo : granulomatous pathology is shaped by the pattern of L-arginine metabolism. J Immunol 2001, 167:6533–6544.CrossRefPubMed
43.
Ma TC, Campana A, Lange PS, Lee HH, Banerjee K, Bryson JB, Mahishi L, Alam S, Giger RJ, Barnes S, Morris SM, Willis DE, Twiss JL, Filbin MT, Ratan RR: A large-scale chemical screen for regulators of the arginase 1 promoter identifies the soy isoflavone daidzeinas a clinically approved small molecule that can promote neuronal protection or regeneration via a cAMP-independent pathway. J Neurosci 2010, 30:739–748.CrossRefPubMedPubMedCentral
44.
Chang NC, Hung SI, Hwa KY, Kato I, Chen JE, Liu CH, Chang AC: A macrophage protein, Ym1, transiently expressed during inflammation is a novel mammalian lectin. J Biol Chem 2001, 276:17497–17506.CrossRefPubMed
45.
Giannetti N, Moyse E, Ducray A, Bondier JR, Jourdan F, Propper A, Kastner A: Accumulation of Ym1/2 protein in the mouse olfactory epithelium during regeneration and aging. Neuroscience 2004, 123:907–917.CrossRefPubMed
46.
Nio J, Fujimoto W, Konno A, Kon Y, Owhashi M, Iwanaga T: Cellular expression of murine Ym1 and Ym2, chitinase family proteins, as revealed by in situ hybridization and immunohistochemistry. Histochem Cell Biol 2004, 121:473–482.CrossRefPubMed
47.
Kitowska K, Zakrzewicz D, Konigshoff M, Chrobak I, Grimminger F, Seeger W, Bulau P, Eickelberg O: Functional role and species-specific contribution of arginases in pulmonary fibrosis. Am J Physiol Lung Cell Mol Physiol 2008, 294:L34-L45.CrossRefPubMed
48.
Witte MB, Barbul A, Schick MA, Vogt N, Becker HD: Upregulation of arginase expression in wound-derived fibroblasts. J Surg Res 2002, 105:35–42.CrossRefPubMed
49.
Jiang J, George SC: TGF-{beta}2 reduces nitric oxide synthase mRNA through a ROCK-dependent pathway in airway epithelial cells. Am J Physiol Lung Cell Mol Physiol 2011, 301:L361–7.CrossRefPubMedPubMedCentral
50.
Boutard V, Havouis R, Fouqueray B, Philippe C, Moulinoux JP, Baud L: Transforming growth factor-beta stimulates arginase activity in macrophages. Implications for the regulation of macrophage cytotoxicity. J Immunol 1995, 155:2077–2084.PubMed
51.
Shearer JD, Richards JR, Mills CD, Caldwell MD: Differential regulation of macrophage arginine metabolism: a proposed role in wound healing. Am J Physiol 1997, 272:E181–190.PubMed
52.
Suzumura A, Sawada M, Yamamoto H, Marunouchi T: Transforming growth factor-beta suppresses activation and proliferation of microglia in vitro . J Immunol 1993, 151:2150–2158.PubMed
53.
Herrera-Molina R, von Bernhardi R: Transforming growth factor-beta 1 produced by hippocampal cells modulates microglial reactivity in culture. Neurobiol Dis 2005, 19:229–236.CrossRefPubMed
54.
Basu A, Krady JK, Enterline JR, Levison SW: Transforming growth factor beta1 prevents IL-1beta-induced microglial activation, whereas TNFalpha- and IL-6-stimulated activation are not antagonized. Glia 2002, 40:109–120.CrossRefPubMed
55.
Dhandapani KM, Brann DW: Transforming growth factor-beta: a neuroprotective factor in cerebral ischemia. Cell Biochem Biophys 2003, 39:13–22.CrossRefPubMed
56.
Wyss-Coray T, Masliah E, Mallory M, McConlogue L, Johnson-Wood K, Lin C, Mucke L: Amyloidogenic role of cytokine TGF-beta1 in transgenic mice and in Alzheimer’s disease. Nature 1997, 389:603–606.CrossRefPubMed
57.
Town T, Laouar Y, Pittenger C, Mori T, Szekely CA, Tan J, Duman RS, Flavell RA: Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like pathology. Nat Med 2008, 14:681–687.PubMedPubMedCentral
58.
59.
60.
Lang R, Patel D, Morris JJ, Rutschman RL, Murray PJ: Shaping gene expression in activated and resting primary macrophages by IL-10. J Immunol 2002, 169:2253–2263.CrossRefPubMed
Metadata
Title
TGFβ signalling plays an important role in IL4-induced alternative activation of microglia
Authors
Xiaolai Zhou
Björn Spittau
Kerstin Krieglstein
Publication date
01-12-2012
Publisher
BioMed Central
Published in
Journal of Neuroinflammation / Issue 1/2012
Electronic ISSN: 1742-2094
DOI
https://doi.org/10.1186/1742-2094-9-210

Other articles of this Issue 1/2012

Journal of Neuroinflammation 1/2012 Go to the issue

Review

New perspectives on central and peripheral immune responses to acute traumatic brain injury

Research

The fatty acid amide hydrolase inhibitor URB597 exerts anti-inflammatory effects in hippocampus of aged rats and restores an age-related deficit in long-term potentiation

Short report

Preserved vascular integrity and enhanced survival following neuropilin-1 inhibition in a mouse model of CD8 T cell-initiated CNS vascular permeability

Research

Etiology of autistic features: the persisting neurotoxic effects of propionic acid

Research

Identification of potential biomarkers of gold nanoparticle toxicity in rat brains

Research

Intravenous immunoglobulin treatment of the post-polio syndrome: sustained effects on quality of life variables and cytokine expression after one year follow up